KR20050113003A - Composition for inhibiting obesity - Google Patents

Abstract

The present invention relates to a composition for inhibiting obesity, and more particularly, to a composition for inhibiting obesity, using the extract of the bark as an active ingredient.

The lacquer bark extract of the present invention significantly reduces the weight of obese experimental animals by high fat diet, reduces the weight of liver, epididymal adipose tissue and post-peritoneal adipose tissue, leukocyte count, erythrocyte count, hemoglobin concentration, Significantly increases general hematologic features, such as platelet count, hematocrit, lymphocyte percentage, monocyte percentage, and multinucleated percentage, and significantly reduces triglycerides, making it a useful medicine for inhibiting obesity.

Description

Composition for inhibiting obesity

The present invention relates to a composition for inhibiting obesity, and more particularly, to a composition for inhibiting obesity, using the extract of the bark as an active ingredient.

Obesity affects all age groups, especially in older adults. It is known that obesity was not so much in the East due to the vegetarian-oriented lifestyle, but in modern times, obesity was gradually increasing in Asians as the eating habits changed and the living environment changed due to the influence of western culture.

In recent years, the economic development of the country, the lifestyle is convenient, and the diet is westernized, the intake of animal foods and the increase of fat intake, overweight and obesity is gradually increasing. The reason for overweight and obesity is that the amount of calories consumed and left over is converted to fat and accumulated in various parts of the body, especially in the subcutaneous tissue and abdominal cavity. In addition, modern man has been reported that physical strength is reduced due to overwork, heavy drinking, stress, etc., about 30-40% have obesity, about 10% of them have severe or pathological obesity has been reported.

Obesity is classified into simple obesity and secondary obesity (symptomatic obesity).

The causes of simplicity obesity include overeating, lack of exercise, and decreased metabolism. The majority of cases that are clinically judged as obesity are simplicity obesity. If obesity manifests and the condition persists, it causes various health disorders.

On the other hand, secondary obesity is obesity caused by any underlying disease, and may include endocrine obesity, hypothalamic obesity, hereditary obesity, or obesity due to drugs.

Obesity is a complication due to various diseases, but obesity itself is diabetes, hypertension, cardiovascular disease, pseudotumor cerebri, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension It is known to cause cholecystitis, osteoarthritis, etc., and causes various diseases or problems such as deactivation of activity.

The main cause of obesity is that the energy consumed continues to be excessive compared to the energy consumed, and some obese patients are trying to lose weight through diet and exercise. In addition, behavioral therapy, psychotherapy, drug therapy or surgery (surgical therapy such as atrophy) is combined.

Diet is a treatment that controls the total energy intake, but weight loss as expected cannot be achieved because the metabolic rate at rest is lowered. There is a problem that causes many physical and mental pains, such as malnutrition, fasting or stress, to the patient.

Exercise therapy not only increases energy consumption, but also improves metabolic rate at rest, corrects insulin resistance, and decreases body fat.However, 20 minutes of aerobic exercise is performed at least three times a week. Since it is necessary to carry out, it is very difficult to carry out continuously.

Behavioral or psychotherapy is a way to maintain diet or exercise therapy, but it is generally difficult to achieve sufficient effects.

When the above treatment method is not effective or when urgent treatment for extreme obesity is necessary, pharmacotherapy or surgical therapy is performed, but the surgical therapy is very burdensome to the patient. The anti-obesity drugs used for drug therapy include appetite suppressants, digestive absorption inhibitors, obesity-inhibiting agents, or metabolic accelerators, but these anti-obesity drugs have a risk of causing side effects such as drug dependence. In addition, there is a problem in that resistance can be developed in a short period of time to a patient to be administered, so that it cannot be used continuously for a long time.

In addition, in the case of exercise therapy, if a forced exercise is applied to an obese person, the risk of injury to the lower extremity joint increases, so it is generally preferable to perform light swimming or the like. In this case, it is considered that one of the preferred methods for improving obesity is to increase muscles in parallel with light exercise such as light swimming and drugs that have little side effects of activating energy metabolism, and to promote energy consumption by increasing basic metabolism. In recent years, there have been many reports that dietary fiber that is low in calories and eliminates fasting is effective for obesity or weight loss (Relser S. Methabolic effects of dietary pection related to Human Health Food Technology. 91-99, 1987; A basic study on the age of Kte: C57BL / 6 mice, Journal of the Korean Society for Laboratory Animal Science, 10 (2): 197-209, 1994).

Therefore, there is an urgent need for the development of new methods or medicines that can be used continuously for long periods of time without burdening the patient with fewer side effects and effectively promoting weight loss.

Meanwhile, Rhus verniciflua Stokes belongs to the family Anacardiaceae, which is a deciduous broad-leaved arboreous tree that grows a lot in Northeast Asia, such as China and Japan. It has been used as a medicine for fever, malaria, hookworm, abdominal pain, pain and constipation, and has been used as food like lacquer chicken. Some studies on the physiological activity of the lacquer tree extract have been reported, and antimicrobial activity against the substances isolated from the lacquer tree, antioxidant activity against the flavonoid component and urushiol component of the sap, and anticancer activity have been reported. However, some of the components of the sumac have been reported to cause allergic dermatitis, which has problems as a drug and food development.

As described above, research on the sap of the lacquer tree has been progressed a lot, but there are few studies on the bark of the lacquer tree, which is known to have no side effects compared to the sap.

Accordingly, the present inventors, while studying the substance for inhibiting obesity in herbal medicine, found that there is an effect of inhibiting obesity in the bark bark extract, and completed the present invention.

The present invention is to provide a composition for inhibiting obesity as an active ingredient of the bark bark extract.

The present invention provides a composition for inhibiting obesity, the extract of the bark bark as an active ingredient.

Hereinafter, the present invention will be described in detail.

The lacquer bark extract included in the composition of the present invention is used by extracting with water, alcohol or a mixed solvent of water and alcohol, and the method of preparing the lacquer bark extract is as follows.

After cutting the sumac bark into a powder using a blender, 70% methanol is added and extracted at 100 ° C for 5 hours. The above extraction process is repeated twice. The extract was left at room temperature, filtered through a filter paper, concentrated under reduced pressure with an evaporation dryer in a 60 ° C. water bath, dissolved in distilled water, left at −70 ° C., and lyophilized with a freeze dryer to obtain a powdery lacquer bark extract.

The lacquer bark extract of the present invention significantly reduces the weight of obese experimental animals by high fat diet, reduces the weight of liver, epididymal adipose tissue and post-peritoneal adipose tissue, leukocyte count, erythrocyte count, hemoglobin concentration, Significantly increases general hematological features such as platelet count, hematocrit, lymphocyte percentage, monocyte percentage and multinucleated percentage, and significantly reduces triglycerides.

Therefore, the lacquer bark extract of the present invention can be used as a medicine useful for inhibiting obesity.

The composition of the present invention may contain one or more active ingredients exhibiting the same or similar function in addition to the lacquer bark extract.

The composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The compositions of the present invention may be administered parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) or orally, depending on the desired method, and the dosage may be based on the weight, age, sex, health status, The range varies depending on diet, administration time, administration method, excretion rate and severity of disease. The daily dosage is 80-120 mg / kg of the lacquer bark extract of the present invention, it is more preferable to administer divided once to several times a day.

The compositions of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the inhibition and treatment of obesity.

Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the contents of the present invention are not limited by the Examples.

Example  : Preparation of Sumac Bark Extract

The lacquer bark (standard number KIOM-01-02) used in this experiment was purchased from Jeongdo C & T (Seoul, Korea) and used for the experiment after confirming the external form in the inspection department of the Korea Institute of Oriental Medicine.

After cutting 600g of the lacquer bark into powder by using a blender, it was put into a round flask and 70% methanol was added and extracted at 100 ° C for 5 hours. The same extraction procedure was repeated twice. The extract was left at room temperature, filtered through a filter paper, concentrated under reduced pressure with an evaporation dryer in a 60 ° C. water bath, dissolved in distilled water, left at −70 ° C., and freeze-dried with a freeze dryer to obtain 104.2 g of powdered lacquer bark extract. .

Experimental Example  : Effect of Sumac bark extract of the present invention on the effect of inhibiting obesity

In order to determine the anti-obesity effect of the bark bark extract of the present invention, the following experiment was performed.

1. Experimental Animal

The experimental animals were used for 3 weeks old C57BL / 6 male mice in Korea Biolink (negative material of Chungbuk) and were adapted to the laboratory environment of the laboratory for 1 week, and then the average body weight was 20.1 ± 0.95g. .

As animal room breeding conditions, temperature 23 ± 3 ℃, relative humidity 55 ± 10%, ventilation frequency 10 ~ 20 times / hour, fluorescent lighting 12 hours / day (8 AM lighting ~ 8 PM light off), illuminance 150 ~ 300 Lux Experimental animals were bred in a polycarbonate breeding box (size: 220 W × 360 L × 200 H mm) in groups of 10 animals per group.

The experimental group was 1) normal group (N + S group) orally administered physiological saline while eating normal diet, 2) obese control group (HF + S group) orally administered physiological saline while eating high fat diet, 3) highland Positive control group (HF + X group) orally administered Xenical (Roche, Switzerland) as a positive control drug while ingesting dietary supplements; 4) Experimental group (HF + RVS) administered orally bark extract with high-fat diet. 10 animals were assigned to each group, and the experiment was conducted for 8 weeks.

2. Dietary and Oral Dosage

The high fat diet was purchased through D12451 (Research Diets; New Jersey, USA) and the regular diet 2018 (Harlan TEKLAD; wisconsin, USA) was used during the experiment.

The oral dose of the drug per experimental animal was recommended as 100mg / kg of lacquer bark extract, and 3 capsules (238mg) per day for the daily dose. It was set as mg / kg. Water and diet were freely ingested, and oral administration was performed 6 times a week at a certain time.

Statistical analysis of the experimental results was carried out using the SPSS package, all measured values were expressed as mean ± standard deviation, and the significance test for the analysis was performed by one way-ANOVA, and the LSD multiple at the level of p <0.05 for the analysis results. A post hoc test was performed to analyze the significance of the mean value of each treatment period.

3. Measurement of body weight, feed intake and feed efficiency

Feed intake and body weight of the test animals were measured twice a week at a given time, and feed efficiency was converted into a percentage of the weight gain to total feed intake.

The results are shown in Table 1 and FIG.

Experimental group Feed Intake (g / day) Weight gain (g / mice) Feed efficiency (%) N + S 2.67 ± 0.23 ^a 0.06 ± 0.03 ^a 2.15 ± 1.19 ^a HF + S 2.03 ± 0.09 ^b 0.11 ± 0.03 ^a 5.37 ± 1.63 ^b HF + X 2.0 ± 0.11 ^b 0.09 ± 0.03 ^ab 4.37 ± 1.68 ^b HF + RVS 1.96 ± 0.04 ^b 0.09 ± 0.03 ^ab 4.43 ± 1.43 ^b

※ 1) N + S (normal group): general diet + physiological saline,

   2) HF + S (obesity control group): high fat diet + saline solution,

   3) HF + X (positive control): high fat diet + zenical (positive control),

   4) HF + RVS (experimental group): high fat diet + lacquer bark extract.

※ a, b, c: p <0.05 between each experimental group

As shown in FIG. 1, the weight change was 21.1 ± 0.5g in the normal group and 22.2 ± 0.9g in the obese control group at 3 weeks after the start of the experiment. Significance by diet remained less than 0.05 until termination (p <0.05). In addition, the positive control group was 21.3 ± 0.1g and the bark bark extract administration group (HF + RVS) of 21.3 ± 0.9g compared to the obese control group having 22.2 ± 0.9g, and the p-values were 0.023 and 0.022, respectively. The experimental group orally administered the lacquer bark extract of the present invention began to appear to significantly reduce the weight compared to the obese control group, and it was observed that the significance was maintained until the end of the experiment. The weight difference between the positive control group and the lacquer bark extract administration group of the present invention throughout the experiment was observed to be insignificant, it can be seen that the lacquer bark extract of the present invention has a similar weight increase inhibitory effect to Jennifer. However, at week 8, the significance between the obesity control group and the positive control group was p value 0.08, and the significance between the obesity control group and the lacquer bark extract administration group of the present invention was p value 0.005, and at the 8th week of the experiment, Body weight decreased significantly.

In addition, as shown in Table 1, the intake of the diet was found to be higher in the group of the general diet intake than the high-fat diet group, which was determined to be due to the relatively high calorie diet high-fat diet In the orally administered group, no difference was observed in feed intake. In the case of weight gain, as the experiment progressed, the obesity control group showed higher weekly weight gain than the normal group, but there was no statistical significance. Feed efficiency decreased by 18.62% and 17.5%, respectively, in the positive control group at 4.37 ± 1.68%, the lacquer bark extract treatment group at 4.43 ± 1.43%, and the obese control group at 5.37 ± 1.63%. .

4. Blood collection and organ and adipose weight measurement

After completion of the experiment, C57BL / 6 mice were fasted for 12 hours, provided with water only, and anesthetized with ethyl ether and dissected. Blood was collected from a single-use syringe with a 1 ml volume in the para-vein and placed in a 1.5 ml micro-tube treated with EDTA K2 to prevent blood coagulation. Subperitoneal adipose tissue was extracted after kidney. The extracted tissue was washed with physiological saline to remove blood, and water was removed with filter paper and weighed.

The results are shown in Table 2.

Experimental group Liver (g) Epididymal Subcutaneous Adipose Tissue (g) Subperitoneal Adipose Tissue After Kidney (g) N + S 0.79 ± 0.04 0.37 ± 0.08 ^a 0.11 ± 0.04 ^a HF + S 0.76 ± 0.04 0.97 ± 0.25 ^b 0.33 ± 0.08 ^b HF + X 0.78 ± 0.65 0.93 ± 0.25 ^b 0.33 ± 0.08 ^b HF + RVS 0.75 ± 0.05 0.83 ± 0.20 ^b 0.30 ± 0.12 ^b

※ 1) N + S (normal group): general diet + physiological saline,

   2) HF + S (obesity control group): high fat diet + saline solution,

   3) HF + X (positive control): high fat diet + zenical (positive control),

   4) HF + RVS (experimental group): high fat diet + lacquer bark extract.

※ a, b: p <0.05 between each experimental group

As shown in Table 2, no significant difference was found between the experimental groups in the liver, and in the epididymal adipose tissue and the post-renal peritoneal adipose tissue, the p-value was 0.001 between the normal diet group and the high-fat diet group. There was a statistically significant difference as follows, the fat tissue was confirmed to increase due to the high-fat diet. In addition, the weight of the epididymal adipose tissue and post-peritoneal adipose tissue in the lacquer bark extract administration group of the present invention was reduced by 14.28% and 9.1%, respectively, compared to the obese control group.

5. Measurement of general hematological properties

Whole blood was measured using leukocyte count, erythrocyte count, hemoglobin concentration, platelet count, hematocrit, lymphocyte percentage, monocyte percentage, and multinucleate percentage using a blood analyzer (coulter JT, Beckman coulter, USA).

The results are shown in Table 3.

Experimental group Leukocyte count (WBC) (× 10 ³ / ml) Lymphocyte percentage (LY) (%) Multinucleus percentage (GR) (%) Monocyte Percentage (MO) (%) Erythrocyte count (RBC) (× 10 ⁶ / ml) Hemoglobin concentration (HB) (g / dl) Hematocrit (Hct) (%) Platelet count (PLT) (× 10 ⁶ / ml) N + S 2.37 ± 0.36 ^a 81.57 ± 4.86 13.13 ± 5.10 5.28 ± 1.10 ^a 9.37 ± 0.19 ^a 14.35 ± 0.38 ^ac 46.18 ± 1.57 ^a 121.77 ± 12.36 ^a HF + S 2.82 ± 0.76 ^a 82.75 ± 6.18 11.15 ± 4.60 5.78 ± 2.22 ^a 9.27 ± 0.18 ^ab 14.17 ± 0.23 ^ab 46.28 ± 1.28 ^a 108.11 ± 14.12 ^b HF + X 2.94 ± 0.30 ^a 84.80 ± 2.49 8.96 ± 2.67 6.24 ± 1.36 ^a 9.11 ± 0.2 ^b 14.04 ± 0.39 ^b 46.59 ± 1.62 ^a 124.10 ± 13.31 ^a HF + RVS 3.20 ± 0.82 ^b 81.67 ± 6.08 11.45 ± 5.48 6.88 ± 1.50 ^b 9.58 ± 0.12 ^c 14.57 ± 0.15 ^c 48.75 ± 1.55 ^b 122.60 ± 22.93 ^a

※ 1) N + S (normal group): general diet + physiological saline,

   2) HF + S (obesity control group): high fat diet + saline solution,

   3) HF + X (positive control): high fat diet + zenical (positive control),

   4) HF + RVS (experimental group): high fat diet + lacquer bark extract.

※ a, b, c: p <0.05 between each experimental group

As shown in Table 3, the results of the general blood test showed no significant difference between the group fed the normal diet and the high-fat diet in all items except the platelet count, and the platelet count was significantly decreased in the obese control group. It became. Items with significant differences were observed between the high-fat diet group and the drug-intake group. In the case of leukocyte count, the lacquer bark extract administration group of the present invention increased significantly (3.20 ± 0.82) × 10 ³ cells / ml compared to the other groups, and in the case of erythrocyte count, the positive control group (9.11 ± 0.2) × 10 ⁶ cells The number of erythrocytes was significantly decreased than that of the normal group, and the prunus bark extract administration group of the present invention was (9.58 ± 0.12) × 10 ⁶ cells / ml, and the p value was significantly increased to 0.05 or less than the other groups. In addition, the hemoglobin and hematocrit levels of the lacquer bark extract group of the present invention were significantly increased to 14.57 ± 0.15 g / ㎗, 48.75 ± 1.55%, respectively.

Therefore, it can be seen that the lacquer bark extract of the present invention significantly increases leukocyte count, erythrocyte count, hemoglobin, hematocrit, platelet levels, and the like.

6. Determination of Biochemical Properties in Plasma

After completing the general blood test, the whole blood was centrifuged and the plasma was separated and stored at -20 ° C. The concentrations of GOT, GPT, blood glucose, triglycerides and cholesterol in plasma were measured using Beckman coulter and Hanlantek's reagent and biochemical analyzer (CX-4, Beckman coulter, USA).

The results are shown in Table 4.

Experimental group GOT (IU / ℓ) GPT (IU / ℓ) Cholesterol (mg / ㎗) Blood glucose level (mg / dl) Triglycerides (mg / dl) N + S 118.0 ± 58.28 32.55 ± 6.18 82.40 ± 7.66 ^a 69.8 ± 25.39 ^a 38.9 ± 16.87 ^a HF + S 125.88 ± 48.60 29.22 ± 8.74 88.88 ± 9.22 ^a 81.55 ± 50.08 ^ab 55.9 ± 34.92 ^a HF + X 128.9 ± 42.21 31.55 ± 9.48 110.0 ± 11.13 ^b 106.60 ± 39.02 ^b 71.5 ± 18.48 ^b HF + RVS 166.7 ± 41.69 36.4 ± 19.60 100.4 ± 14.15 ^b 69.1 ± 27.47 ^a 41.0 ± 8.41 ^ac

※ 1) N + S (normal group): general diet + physiological saline,

   2) HF + S (obesity control group): high fat diet + saline solution,

   3) HF + X (positive control): high fat diet + zenical (positive control),

   4) HF + RVS (experimental group): high fat diet + lacquer bark extract.

※ a, b, c: p <0.05 between each experimental group

As shown in Table 4, the concentrations of GOT and GPT were not significant among all groups, and hepatotoxicity was not observed by the lacquer bark extract of the present invention. In the case of triglycerides, the concentration of triglycerides of the lacquer bark extract administration group of the present invention was reduced by 26.65% to 41.0 ± 8.41 mg / dl of the lacquer bark extract administration group of the present invention and 55.9 ± 34.92 mg / dl of the obese control group. In particular, the prunus bark extract administration group of the present invention significantly reduced the p value to 0.004 compared to the positive control group. Triglycerides in the positive control group are higher than the obese control group because they cannot inactivate lipolytic enzymes and hydrolyze it into monoglycerides and free fatty acids that can absorb triglycerides of dietary fat. Serides are not absorbed into the body and most of them are excreted outside the body, but some of them remain in the blood.

Examples of preparations for the compositions of the present invention are illustrated below.

Formulation example  : Preparation of Pharmaceutical Formulations

1. Preparation of powder

2 g of Sumac bark extract

1g lactose

The above ingredients were mixed and filled in airtight cloth to prepare a powder.

2. Preparation of Tablets

Sumac bark extract 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

Sumac bark extract 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

The lacquer bark extract of the present invention significantly reduces the weight of obese experimental animals by high fat diet, reduces the weight of liver, epididymal adipose tissue and post-peritoneal adipose tissue, leukocyte count, erythrocyte count, hemoglobin concentration, Significantly increases general hematologic features, such as platelet count, hematocrit, lymphocyte percentage, monocyte percentage, and multinucleated percentage, and significantly reduces triglycerides, making it a useful medicine for inhibiting obesity.

1 is a view showing the effect of the bark bark extract of the present invention on the weight change of obese experimental animals by high fat diet.

Claims (3)

Obesity-inhibiting composition comprising the extract of the bark as an active ingredient. According to claim 1, The bark bark extract is a composition for inhibiting obesity, characterized in that obtained by extraction with water, alcohol or a mixed solvent of water and alcohol. The composition for inhibiting obesity according to claim 2, wherein the alcohol is methanol.